Funding for this research was provided by:
national institutes of health (CA111412, CA65492, CA197292)
dod peer reviewed cancer research program (CA200922)
Article History
Received: 15 July 2021
Accepted: 21 October 2021
First Online: 12 April 2022
Declarations
:
: Not applicable.
: Not applicable.
: PRK declares no competing interests. MF consults for, holds stock in and receives research funds from GT BioPharma (all unrelated to the content of this manuscript). JSM consults for and holds stock in Fate Therapeutics and GT BioPharma and receives research funds from these entities (all unrelated to the content of this manuscript). JSM serves on the Scientific Advisory Board of ONK Therapeutics, Magenta, and Wugan. He also consults for Vycellix. These interests have been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policy.